April 2022
Gordon Barker, Amprologix CEO was selected to present our innovative antibiotic development approach at the Start-ups Session (https://amr-conference.com/start-ups-amr-conference-pitching-session/). The session, sponsored by INCATE and partners, was watched by potential investors and funders and included SMEs developing novel therapies through to vaccines and diagnostics.
Gordon presented our approach that aims to make antibiotic R&D profitable again. Currently, development costs for much needed antibiotics are prohibitive, far outweighing the income generated through sales. A range of innovative plans are now being trialled, including in the UK NHS to improve reimbursement and incentivise antibiotic R&D. However, our approach could bring new antibiotics to market for <$30m, making the returns (>$280m) very attractive.
